Table 5.
Drug treatment during the study period
| Variables | Admission | Discharge | 3-month follow-up | 12-month follow-up |
|---|---|---|---|---|
| Oral anticoagulants* (%) | 100 | 100 | 100 | 67.3 |
| Aspirin (%) | 11.4 | 2.9 | 5.4 | 7.7 |
| Beta-blockers (%) | 37.1 | 47.1 | 50.0 | 44.2 |
| ACE inhibitors (%) | 21.4 | 22.9 | 23.2 | 26.9 |
| ARBs (%) | 32.9 | 32.9 | 33.9 | 36.5 |
| Calcium channel blockers (%) | 24.3 | 30.0 | 26.8 | 23.1 |
| Statins (%) | 18.6 | 30.0 | 23.2 | 23.1 |
| Insulin (%) | 5.7 | 5.7 | 3.6 | 1.9 |
| Oral antidiabetics (%) | 12.9 | 12.9 | 14.3 | 9.6 |
| Antidepressants (%) | 14.3 | 14.3 | 8.9 | 11.5 |
Note:
*
Rivaroxaban in all patients.
Abbreviations: ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor blocker.